Registration is now open for the 13th annual meeting of the Congress on Targeted Anticancer Therapies, which will take place in France.
Targeted Anticancer Therapies (TAT) congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical development, supplemented by associated translational research.
TAT congresses provide a place where the world's leaders in early-phase development of new cancer therapeutics gather annually, establish and renew professional and personal relationships, exchange views, discuss matters of common interest, and establish new collaborations.
"TAT has a unique setting, because you have one single room where everything happens," says Professor Jean-Charles Soria, TAT 2015 President.
"The size allows for direct and friendly interactions between key opinion leaders, young investigators and industry."
Registration and abstract submission will remain open until 31 December, 2014.